PMID- 10622546
OWN - NLM
STAT- MEDLINE
DCOM- 20000124
LR  - 20191103
IS  - 1401-7431 (Print)
IS  - 1401-7431 (Linking)
VI  - 33
IP  - 6
DP  - 1999
TI  - Tumor necrosis factor-alpha serum activity during treatment of acute 
      decompensation of cachectic and non-cachectic patients with advanced congestive 
      heart failure.
PG  - 344-50
AB  - Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine that 
      produces left ventricular dysfunction and a negative inotropic effect in cardiac 
      tissue when overexpressed in human subjects. Previous studies have shown that 
      levels of circulating TNF-alpha are elevated in patients with advanced congestive 
      heart failure (CHF) and especially in those with cardiac cachexia. To clarify the 
      potential role of TNF-alpha in the unstable state of decompensated advanced CHF, 
      we investigated the TNF-alpha serum activity in 25 cachectic and 22 non-cachectic 
      CHF patients (New York Heart Association, NYHA functional classes III or IV), who 
      were treated with intravenous diuretics and positive inotropic agents for acute 
      decompensation of the disease, during a 5-day hospitalization period, as well as 
      in 15 age-matched healthy control subjects. Cachectic CHF patients needed higher 
      dosages of inotropic agents than non-cachectic patients and the determination of 
      TNF-alpha serum concentrations in this patient group showed high levels of 
      TNF-alpha at hospital admission (18.3 +/- 3.2 pg/ml) and a transient increase in 
      circulating TNF-alpha during the treatment period with the highest levels on the 
      2nd day of hospitalization (32.5 +/- 7.1 pg/ml). The TNF-alpha serum levels were 
      low in non-cachectic CHF patients and healthy controls on the 1st day (4.0 +/- 
      0.9 and 3.7 +/- 0.6 pg/ml, respectively) and did not change substantially during 
      the course of the study. The present results show that TNF-alpha serum activity 
      is transiently increased during the treatment of decompensated cachectic CHF 
      patients only and may be related to the clinical instability and the consequent 
      therapeutic interventions in this category of CHF patients.
FAU - Parissis, J T
AU  - Parissis JT
AD  - 1st Department of Cardiology, Amalia Fleming Hospital, Athens, Greece.
FAU - Venetsanou, K F
AU  - Venetsanou KF
FAU - Mentzikof, D G
AU  - Mentzikof DG
FAU - Ziras, N G
AU  - Ziras NG
FAU - Kefalas, C G
AU  - Kefalas CG
FAU - Karas, S M
AU  - Karas SM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Scand Cardiovasc J
JT  - Scandinavian cardiovascular journal : SCJ
JID - 9708377
RN  - 0 (Biomarkers)
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Diuretics)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 3S12J47372 (Dobutamine)
RN  - 73K4184T59 (Digoxin)
RN  - 7LXU5N7ZO5 (Furosemide)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - Body Mass Index
MH  - Cachexia/blood/*drug therapy/etiology
MH  - Cardiotonic Agents/therapeutic use
MH  - Digoxin/therapeutic use
MH  - Diuretics/therapeutic use
MH  - Dobutamine/administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Furosemide/administration & dosage/therapeutic use
MH  - Heart Failure/*blood/complications/drug therapy
MH  - Humans
MH  - Injections, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Myocardial Contraction/drug effects
MH  - Prognosis
MH  - Tumor Necrosis Factor-alpha/*metabolism
EDAT- 2000/01/06 00:00
MHDA- 2000/01/06 00:01
CRDT- 2000/01/06 00:00
PHST- 2000/01/06 00:00 [pubmed]
PHST- 2000/01/06 00:01 [medline]
PHST- 2000/01/06 00:00 [entrez]
AID - 10.1080/14017439950141407 [doi]
PST - ppublish
SO  - Scand Cardiovasc J. 1999;33(6):344-50. doi: 10.1080/14017439950141407.